Radionuclide Therapy for Neuroendocrine Tumors.

@article{Cives2017RadionuclideTF,
  title={Radionuclide Therapy for Neuroendocrine Tumors.},
  author={Mauro Cives and Jonathan R. Strosberg},
  journal={Current oncology reports},
  year={2017},
  volume={19 2},
  pages={9}
}
Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared 177Lu-DOTATATE versus high-dose octreotide… CONTINUE READING
9 Citations
73 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 73 references

NETTER-1 Trial Investigators

  • M Lopera Sierra, P Santoro, +4 authors E. Krenning
  • N Engl J Med
  • 2017

R a d i o l a b e l e d s oma t o s t a t i n a n a l o g u e t h e r a p y o f gastroenteropancreatic cancer

  • L Bodei, DJ Kwekkeboom, M Kidd, IM Modlin, EP. Krenning
  • Semin Nucl Med
  • 2016

A critical review of alpha radionuclide therapy — how to deal with recoiling daughters ?

  • RM deKruijff, HT Wolterbeek, AG Denkova
  • Pharmaceuticals ( Basel )
  • 2015

A critical review of alpha radionuclide therapy—how to deal with recoiling daughters? Pharmaceuticals (Basel)

  • RM de Kruijff, HT Wolterbeek, AG. Denkova
  • 2015

Similar Papers

Loading similar papers…